Zithromac Iv Special Investigation For Legionella Infection.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 21
- 主要终点
- Number of Participants With Treatment-Related Adverse Events
研究概览
简要总结
To collect retrospectively the efficacy and safety information of azithromycin IV on patients with Legionnaires' disease related to their appropriate use in daily practice.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients who are prescribed Azithromycin (Zithromac) IV for Legionnaires' disease.
排除标准
- •Patients who have been prescribed Zithromac or Zithromac SR.
研究组 & 干预措施
Azithromycin IV
Subjects who are treated with Azithromycin IV for Legionnaires' disease
干预措施: Azithromycin IV (Drug)
结局指标
主要结局
Number of Participants With Treatment-Related Adverse Events
时间窗: 29 days
A treatment-related adverse event was any untoward medical occurrence attributed to Zithromac Intravenous use (and Zithromac Tablets) in a participant who received Zithromac Intravenous use. A treatment-related serious adverse event was a treatment-related adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; lifethreatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Relatedness to Zithromac Intravenous use (and Zithromac Tablets) was assessed by the physician.
次要结局
- Clinical Effectiveness Rate in Participants(29 days)